Photographs are used for representational functions solely. |Photograph offered by: Reuters
Solar Pharmaceutical Industries Ltd. introduced that it has acquired approval from the Drug Controller Common of India (DCGI) to fabricate and promote a generic model of semaglutide injection.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for continual weight administration in adults as an adjunct to a reduced-calorie weight-reduction plan and elevated bodily exercise.
Solar Pharma introduced that it plans to launch generic semaglutide injection beneath the model identify ‘Nobeltreat’ after the expiration of the semaglutide patent in India.
The product has been permitted by the DCGI following evaluation of a Part III medical trial performed in India.
Noveltreat is available in 5 dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, with a upkeep dose of two.4 mg as soon as weekly.
This product is run through an easy-to-use prefilled pen designed to help handy and correct dosing.
“Weight problems and diabetes have emerged as two of essentially the most urgent well being challenges dealing with India, and GLP-1-based therapies can play a significant function in addressing this rising burden. Nobeltreat meets international high quality requirements and is supported by sturdy medical proof in India for its effectiveness and security in weight administration,” stated Kirti Ganokhar, Managing Director, Solar Pharma.
“As India’s largest pharmaceutical firm with management in cardiometabolic remedy, we’re dedicated to enhancing entry to generic semaglutide throughout India post-patent expiry,” he added.
In December 2025, Solar Pharma acquired DCGI approval to fabricate and market semaglutide injection as an adjunct to weight-reduction plan and train for the therapy of adults with poorly managed kind 2 diabetes.
As soon as the patent for semaglutide expires in India, will probably be marketed beneath the model identify SemaTrinity.
